Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Convergence 2020 has come and gone, but you can still access recorded sessions, which are available to attendees until 31 December 2020.
This year, our European regulatory community will converge online with a fully virtual program that will allow attendees to experience Euro Convergence live online from the safety and comfort of their homes.
RAPS' “how to” guide to developing a comprehensive global regulatory strategy for all types of medical devices. Updated September 2020.
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.
Posted 26 June 2012
A legislative proposal to limit the ease with which regulatory agencies are able to compel companies to enter into consent decrees is rapidly advancing in the House of Representatives.
The Sunshine for Regulatory Decrees and Settlements Act (SRDSA) of 2012 (H.R. 3862) received approval from the Committee on the Judiciary on 27 March 2012 in a 20-10 vote.
As Regulatory Focus reported in February, consent decrees are often used by the US Food and Drug Administration (FDA) to settle charges between manufacturers and the agency. A prominent example is FDA's 26 January 2012 consent decree against Indian generics manufacturer Ranbaxy, which compels the company to make changes in light of manufacturing problems at some of its facilities.
To Republican members of the House's Committee on the Judiciary, these actions are seen as having deleterious effects on companies.
"A heavy contributor to the burden of new regulation is the use of consent decrees and settlement agreements to force federal agencies to issue new rules," Judiciary Chairman Lamar Smith (R-TX) said in a statement. "Those to be regulated typically do not know about these deals until the plaintiffs' complaints and the proposed decrees or settlements are filed in court. By then, it is too late."
Under SRDSA, agencies would be unable to seek a consent decree with a company until after other affected parties were able to intervene in the action. This would allow the public and industry to comment on any pending consent decrees through the use of a comment period and the acceptance of amicus curiae briefs with the court and agency.
The Congressional Budget Office's (CBO) scored the legislation as having a minor budgetary impact of $7 million through 2017 largely as the result of the consent decree process taking longer and consuming additional agency resources.
CBO's scoring is usually the final process before a piece of legislation is brought up for a vote before the entire House of Representatives.
Read more:
CBO - H.R. 3862, Sunshine for Regulatory Decrees and Settlements Act of 2012
House - Markup of Sunshine for Regulatory Decrees and Settlements Act (SRDSA) of 2012
Chairman Smith - Statement on SRDSA
Regulatory Focus - Proposed Bill Would Limit Use of Consent Decrees, Settlement Agreements
Tags: SRDSA, Sunshine for Regulatory Decrees and Settlements Act, Settlement, Legislation, Consent Decree, House, Latest News, regulation, regulatory
Regulatory Focus newsletters
All the biggest regulatory news and happenings.